Related Experiment Video
Updated: Aug 23, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective
Niki M Zacharias1, Eric S Rupe1, Xinyue Chen2
1The University of Texas MD Anderson Cancer Center Houston, TX United States.
Purpose:
SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically actionable dependency in RMC and translated this insight into a deployable clinical regimen.
Experimental Design:
EGFR expression was assessed by CLIA-certified immunohistochemistry in RMC tumors and by integrated RNA- and chromatin immunoprecipitation-sequencing of primary tumors and adjacent kidney. Panitumumab was compared with erlotinib in patient- and cell line-derived xenografts, and its mechanism defined by immunoblotting, confocal colocalization, cell-cycle and apoptosis assays, and natural killer (NK) cell co-culture. Panitumumab-based therapy was then evaluated prospectively in 26 patients with RMC across ten centers on two continents.
Results:
RMC showed uniformly high membranous EGFR (median H-score 300), with enhancer and promoter reprogramming at the EGFR locus and a ligand switch from EGF to epiregulin and amphiregulin. EGFR expression was uncoupled from SMARCB1 status in vitro. Panitumumab outperformed erlotinib in RMC xenografts, suppressed AKT and ERK1/2 signaling, and routed EGFR to LAMP1-positive lysosomes in vitro; its effect was predominantly cytostatic, with minimal NK cell-mediated cytotoxicity. Clinically, panitumumab-based therapy achieved a 53.9% objective response rate, including 15.4% complete responses, with median progression-free and overall survival of 5.8 and 9.5 months.
Conclusions:
Wild-type EGFR is a foundational dependency in RMC that is effectively targeted by panitumumab-based therapy. These findings, derived from a non-randomized registry, provide a biological and clinical rationale for further prospective validation.
Insights
SMARCB1-deficient renal medullary carcinoma (RMC) is a rare cancer. Targeting wild-type epidermal growth factor receptor (EGFR) with panitumumab showed promising results in patients with RMC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare and aggressive kidney cancer.
- RMC is refractory to standard renal cell carcinoma therapies, necessitating novel treatment strategies.
- Randomized trials are challenging due to the rarity of RMC.
Purpose of the Study:
- To investigate wild-type epidermal growth factor receptor (EGFR) as a potential therapeutic target in RMC.
- To translate findings into a clinically applicable treatment regimen for RMC.
Main Methods:
- EGFR expression assessed via immunohistochemistry and sequencing.
- Panitumumab efficacy compared to erlotinib in xenograft models.
- Mechanism of action studied using cell-based assays and co-culture models.
- Prospective evaluation of panitumumab-based therapy in RMC patients.
Main Results:
- RMC tumors exhibited uniformly high membranous EGFR expression.
- Panitumumab demonstrated superior efficacy over erlotinib in RMC xenografts.
- Panitumumab therapy achieved a 53.9% objective response rate in RMC patients.
- Median progression-free survival was 5.8 months and overall survival was 9.5 months.
Conclusions:
- Wild-type EGFR is a critical dependency in RMC.
- Panitumumab-based therapy is an effective treatment for RMC.
- Further prospective validation of these findings is warranted.
